Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 10,000 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 10,000 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $32.13, for a total transaction of $321,300.00. Following the transaction, the chief operating officer now owns 206,286 shares of the company’s stock, valued at approximately $6,627,969.18. The trade was a 4.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Jonathan Young also recently made the following trade(s):

• On Friday, November 1st, Jonathan Young sold 50,716 shares of Akero Therapeutics stock. The shares were sold at an average price of $31.57, for a total transaction of $1,601,104.12.
• On Monday, October 14th, Jonathan Young sold 40,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.15, for a total transaction of $1,206,000.00.
• On Tuesday, October 1st, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $28.18, for a total transaction of $281,800.00.
• On Tuesday, September 10th, Jonathan Young sold 568 shares of Akero Therapeutics stock. The shares were sold at an average price of $26.18, for a total transaction of $14,870.24.

Akero Therapeutics Stock Up 0.6 %

Shares of NASDAQ:AKRO traded up $0.17 during midday trading on Wednesday, reaching $30.92. The company’s stock had a trading volume of 1,403,930 shares, compared to its average volume of 856,359. The firm has a market capitalization of $2.16 billion, a P/E ratio of -8.25 and a beta of -0.23. The firm has a 50 day moving average of $30.59 and a 200-day moving average of $26.61. Akero Therapeutics, Inc. has a 12-month low of $15.32 and a 12-month high of $37.00. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05.

Akero Therapeutics (NASDAQ:AKRO) last posted its earnings results on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.15). On average, research analysts anticipate that Akero Therapeutics, Inc. will post -3.96 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on AKRO shares. Citigroup started coverage on shares of Akero Therapeutics in a research note on Monday, November 18th. They issued a “buy” rating and a $65.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Akero Therapeutics in a research note on Monday, November 18th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $46.83.

Hedge Funds Weigh In On Akero Therapeutics

Several institutional investors have recently made changes to their positions in AKRO. Barclays PLC increased its holdings in Akero Therapeutics by 127.9% in the 3rd quarter. Barclays PLC now owns 127,668 shares of the company’s stock worth $3,662,000 after acquiring an additional 71,652 shares in the last quarter. Y Intercept Hong Kong Ltd boosted its position in shares of Akero Therapeutics by 13.8% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 16,916 shares of the company’s stock valued at $485,000 after acquiring an additional 2,049 shares during the last quarter. XTX Topco Ltd bought a new stake in Akero Therapeutics in the third quarter worth $308,000. Wellington Management Group LLP lifted its position in Akero Therapeutics by 54.4% in the third quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock worth $226,554,000 after buying an additional 2,782,029 shares during the last quarter. Finally, RTW Investments LP lifted its position in shares of Akero Therapeutics by 9.0% during the third quarter. RTW Investments LP now owns 5,919,435 shares of the company’s stock worth $169,829,000 after purchasing an additional 487,450 shares during the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.